Cytotoxic innate-like T cell killer (ILTCK)

Cytotoxic innate-like T cell killers (ILTCKs) are a distinct subset of T cells with features bridging innate and adaptive immunity. Unlike conventional CD8+ or CD4+ T cells, ILTCKs express T-cell receptors (both αβ and γδ types) that can respond to non-peptide antigens, stress molecules, or tumor-associated signals independent of classical MHC presentation[1][5][2]. ILTCKs accumulate in tumors, where they are highly cytotoxic—expressing granzyme B, perforin, and TRAIL—and can kill transformed cells and influence adaptive immune responses. These cells often express markers typical of NK cells and are driven by cytokines such as IL-15. Their unique phenotype and gene signature distinguish them from conventional T cells, NK cells, and other lymphoid lineages, with potential applications for immunotherapy, including CAR-T strategies and treatments aiming to expand ILTCKs within tumors, particularly for patients resistant to traditional immune checkpoint blockade[1][5][7]. The phrase "Tumor cells via innate-like T-cell receptor" incorrectly conflates tumor targets with the effector cells' receptor; there is no single canonical receptor named this way. The therapeutic target described here is a cellular mechanism/process, not a defined molecular entity[1][5][2][7]. If you seek structured data, focus on “Cytotoxic innate-like T cell killer (ILTCK)” or a specific population such as “γδ T cell”, “iNKT cell”, or “MAIT cell”, each with their own molecular details.

Other names

Cytotoxic innate-like T cell killerInnate-like T cell (ILT)Innate-like T lymphocyteILTCKNK-like T cellunconventional T cellγδ T cellinvariant natural killer T cell (iNKT)mucosal-associated invariant T cell (MAIT)

Antitumor cytotoxicity via unconventional TCR-mediated recognition. Release of cytotoxic molecules (granzyme B, perforin, TRAIL). Cytokine production (IFN-γ, IL-17A). Activation by non-peptide antigens or cell-stress signals, independent of classical MHC recognition.